Outcomes of Cord Blood Vs Adult Stem Cell Sources in Patients with Mutated TP53 Myeloid Malignancies

Nora Chokr(Cornell University), Alexandra Gomez-Arteaga(Cornell University), Joshua Fein(Dana-Farber Cancer Institute), Koen van Besien(University Hospitals of Cleveland), Adrienne A. Phillips(Palmetto Hematology Oncology), Tsiporah B. Shore(Cornell University), Pinkal Desai(NewYork–Presbyterian Hospital), Ellen K. Ritchie(Cornell University), Jingmei Hsu(Cancer Research Institute), Sebastian Mayer(Mount Sinai Hospital), Danielle Guarneri(Palmetto Hematology Oncology), Michael Samuel(NewYork–Presbyterian Hospital), Gail J. Roboz(Cornell University)
Transplantation and Cellular Therapy
February 1, 2023
10.1016/s2666-6367(23)00218-x
Cited by 0

Related Papers

Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
|Science Translational Medicine|2014|2.5k
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
|Blood|2017|1.5k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Engraftment of Allogeneic Hematopoietic Progenitor Cells With Purine Analog-Containing Chemotherapy: Harnessing Graft-Versus-Leukemia Without Myeloablative Therapy
|Blood|1997|1.2k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k